Sight Sciences, Inc. (NASDAQ:SGHT) Insider Jeremy B. Hayden Sells 4,864 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,864 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.52, for a total transaction of $17,121.28. Following the sale, the insider now directly owns 153,823 shares in the company, valued at approximately $541,456.96. This represents a 3.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sight Sciences Stock Up 0.3 %

NASDAQ:SGHT opened at $3.32 on Thursday. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 12-month low of $3.20 and a 12-month high of $8.45. The stock’s fifty day simple moving average is $3.89 and its 200-day simple moving average is $5.56. The firm has a market capitalization of $168.51 million, a P/E ratio of -3.25 and a beta of 2.57.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The business had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. Equities research analysts expect that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on SGHT. Lake Street Capital cut shares of Sight Sciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $10.00 to $5.00 in a research note on Monday, November 4th. Piper Sandler reissued a “neutral” rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. UBS Group assumed coverage on Sight Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $5.50 target price for the company. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Friday, November 8th. Finally, Morgan Stanley dropped their price objective on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.12.

Institutional Investors Weigh In On Sight Sciences

Several large investors have recently modified their holdings of SGHT. American Century Companies Inc. lifted its stake in Sight Sciences by 31.1% in the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after buying an additional 8,527 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in Sight Sciences by 5.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock worth $1,174,000 after purchasing an additional 10,000 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Sight Sciences by 40.1% in the 2nd quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock valued at $272,000 after purchasing an additional 11,671 shares during the period. SG Americas Securities LLC bought a new stake in shares of Sight Sciences in the third quarter valued at about $75,000. Finally, Geode Capital Management LLC boosted its position in shares of Sight Sciences by 1.6% during the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after buying an additional 12,709 shares during the period. 55.51% of the stock is currently owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.